REGENERON PHARMACEUTICALS, INC. (REGN) vs VERTEX PHARMACEUTICALS INC / MA (VRTX)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | REGN | VRTX |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $14.34B | $12B |
| Revenue growth (YoY) | ▲ 1.0% | ▲ 8.9% |
| Net income | $4.5B | $3.95B |
| Gross margin | — | 86.2% |
| Diluted EPS | $41.48 | $15.32 |
| Insider net (6 mo) | +2.3K sh • 7 sells • 0 buys | +809 sh • 14 sells • 0 buys |
| Institutional owners | 45 | 47 |
| Institutional value held | $38.9B | $86.39B |
| Next earnings (est.) | Around Jan 11, 2027 | Nov 2, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About REGENERON PHARMACEUTICALS, INC. (REGN)
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular… Read more →
About VERTEX PHARMACEUTICALS INC / MA (VRTX)
Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing transformative medicines for people with serious diseases, concentrating on specialty markets. Read more →
Source: SEC EDGAR.